



Published in final edited form as:

Tetrahedron Lett. 2003 May 12; 44(20): 3967–3969. doi:10.1016/S0040-4039(03)00744-5.

An enantioselective synthesis of the C₁–C₉ segment of antitumor macrolide peloruside A

Arun K. Ghosh* and Jae-Hun Kim

Department of Chemistry, University of Illinois at Chicago, 845 West Taylor Street, Chicago, IL 60607, USA

Abstract

A stereocontrolled synthesis of the C₁–C₉ segment of the marine natural product peloruside A is described. The key steps involve Sharpless's catalytic asymmetric dihydroxylation reaction, a chelation-controlled reduction of chiral β-alkoxy ketones to elaborate the *syn*-1,3-diol functionality and a ring-closing olefin metathesis of a homoallylic alcohol-derived acrylate ester to form an α,β-unsaturated δ-lactone.

Macrocyclic marine natural products continue to be a rich source for potent antitumor agents with unique structural features.¹ However, in many instances scarcity of natural abundance has hindered subsequent in-depth biological studies. Peloruside A, a 16-membered macrolide was recently isolated from the New Zealand marine sponge *Mycale hentscheli*.² It displayed potent cytotoxicity against P388 murine leukemia cells at 10 ng/mL. It induces biochemical changes consistent with apoptosis in a number of cultured mammalian cell lines.^{3a} More recently, it has been shown that peloruside A exhibits microtubule-stabilizing activity and arrests cells in the G₂-M phase of the cell cycle similar to paclitaxel.^{3b} Peloruside A has structural similarity to epothilones which are undergoing clinical trials.⁴ Peloruside A contains ten stereogenic centers and its structure and relative stereochemistry have been elucidated by extensive NMR studies.² As part of our continuing interest in the chemistry and biology of complex natural products with potent antimetabolic properties,⁵ we became intrigued by the unique structural features of peloruside A along with its significant anti-tumor properties. Moreover, scarcity of its supply has precluded its in-depth biological evaluation. Thus far, Paterson and co-workers have only reported the synthesis of various fragments of peloruside A.⁶ Herein, we describe a convenient enantioselective synthesis of the C₁–C₉ segment of peloruside A where all five stereo-genic centers have been constructed by asymmetric synthesis.

As depicted in Figure 1, our synthetic strategy to peloruside A is convergent and involves the assembly of fragments **2** (C₁–C₉ segment) and **3** (C₁₀–C₂₄ segment) by an aldol reaction and subsequent macrolactonization between the C₁-carboxylic acid and C₁₅-hydroxyl group. The synthesis of the C₁–C₉ segment commenced with the preparation of α,β-unsaturated ester **4** using known procedures.⁷ As shown in Scheme 1, ester **4** was transformed into optically active alcohol **5** by a three-step sequence involving: (1) Sharpless asymmetric

*Corresponding author. arunghos@uic.edu.

dihydroxylation⁸ reaction with AD mix- α in the presence of methanesulfonamide in a mixture (1:1) of *t*-BuOH and H₂O at 0°C provided the corresponding diol in 90% ee;⁹ (2) exposure of the resulting diol to dimethoxypropane in the presence of a catalytic amount of PPTS to form the isopropylidene derivative; and (3) reduction of the ester with lithium borohydride.

The overall procedure is very convenient and provided desired optically active alcohol **5** in 80% yield (three steps) after silica gel chromatography $\{[\alpha]_D^{23} = -9.62 (c 0.52, \text{CHCl}_3)\}$.

Protection of alcohol **5** as a benzyl ether provided **6** in multigram quantities. Removal of the TBDPS group followed by Dess–Martin oxidation¹⁰ of the resulting alcohol in CH₂Cl₂ in the presence of NaHCO₃ for 2 h provided aldehyde **7** in 87% yield.

To install the 1,3-diol functionality selectively, aldehyde **7** was subjected to Brown's asymmetric allylboration protocol with allyldiisopinocampheylborane to provide homoallylic alcohol **8** diastereoselectively in 71% yield.¹¹ A diastereomeric ratio of 83:17 was determined by ¹H and ¹³C NMR analysis. In an alternative procedure, aldehyde **7** was also converted to alcohol **8** diastereoselectively using chelation-controlled reduction as the key step. Thus, treatment of **7** with allylmagnesium bromide provided a diastereomeric mixture (*syn:anti*=42:58 by ¹H NMR analysis) of alcohols **8** and **9** in 74% yield. The mixture of alcohols **8** and **9** was oxidized by Dess–Martin periodinane¹⁰ to give the corresponding β -ketone in 88% yield. A chelation-controlled reduction by LAH in the presence of LiI at -78°C in ether provided alcohol **8** diastereoselectively (*syn:anti*=91:9 by ¹H NMR analysis) in 87% yield.¹² The observed diastereoselectivity can be rationalized by stereochemical model **10** in which, due to the presence of the *gem*-dimethyl group on the β -face, the carbonyl reduction proceeded from the less hindered α -face providing **8** selectively. This three-step sequence is operationally simple and provided convenient access to desired alcohol **8**. Our next plan was to form an α,β -unsaturated δ -lactone and then elaborate the 1,2-diol functionality at C₇ and C₈ stereoselectively. For the synthesis of the corresponding α,β -unsaturated δ -lactone, we utilized the ring-closing olefin metathesis protocol described by us recently.¹³ As shown, alcohol **8** was reacted with acryloyl chloride and Et₃N in CH₂Cl₂ at 0°C to afford acrylate ester **11**. Acrylate ester **11**, upon exposure to a catalytic amount of first generation commercial Grubbs's catalyst¹⁴ (10 mol%) in CH₂Cl₂ at 40°C for 14 h, provided α,β -unsaturated δ -lactone **12** in 90% yield after silica gel chromatography.

To append the C₇ and C₈-1,2-diol functionality, we attempted catalytic osmylation of α,β -unsaturated δ -lactone **12** in aqueous acetone (Scheme 2). This has however, provided undesired diol **13** as a single diastereomer in 67% yield. The depicted stereochemistry was assigned based upon NOESY experiments. Sharpless's asymmetric dihydroxylation⁸ of **12** with AD mix- β did not proceed even after prolonged (24 h) reaction time at 23°C. This prompted us to investigate asymmetric dihydroxylation of the corresponding open chain α,β -unsaturated ester. Thus, saponification of lactone **12** with aqueous sodium hydroxide was followed by protection of the resulting hydroxy acid as the corresponding TBDMS protected derivative.¹⁵ Esterification of the resulting acid with diazomethane afforded methyl ester **14** in 80% yield over three steps. This *cis*- α,β -unsaturated ester was then subjected to asymmetric dihydroxylation with AD mix- β at 0°C for 72 h. This afforded a

mixture of diastereomeric *cis*-1,2-diols in 72% yield with the major product (**15**) being the desired diastereomer (diastereomeric ratio 91:9 was determined by ^1H and ^{13}C NMR analysis). The diastereomers were separated by silica gel chromatography. The depicted stereochemistry of **15** and **16** are based upon subsequent stereochemical assignment of lactone **17**. It should be noted that catalytic osmylation of **14** at 23°C for 6 h afforded the *cis*-1,2-diols **15** and **16** as a 1:1 mixture of diastereomers in 85% yield. Diol **15** was converted to δ -lactone **17** as follows. Treatment of **15** with $n\text{Bu}_4\text{N}^+\text{F}^-$ in THF resulted in removal of TBDMS group and concomitant lactonization. Protection of the diol functionality with dimethoxypropane and a catalytic amount of PPTS furnished isopropylidene derivative **17** in 63% over two steps.¹⁶ Stereochemical assignment of **17** was based upon NOESY experiments. The spatial proximity of the protons H_a (δ 4.24 ppm), H_b (δ 4.58 ppm) and H_c (δ 4.44 ppm) is clearly evident in the NOESY spectrum. Either derivative of **15** or **17** is now suitable for the synthesis of peloruside A.

In summary, a stereocontrolled synthesis of the C_1 – C_9 fragment of peloruside A has been achieved. The key steps are the Sharpless asymmetric dihydroxylation reaction, Grubbs' ring-closing olefin metathesis and a chelation-controlled reduction of a chiral β -alkoxy ketone to install the *syn*-1,3-diol functionality stereoselectively. Further work toward the total synthesis of peloruside A is in progress.

Acknowledgements

This research work was supported in part by Merck Research Laboratories and the National Institutes of Health.

References

1. Harris CR; Danishefsky SJ J. Org. Chem 1999, 64, 8434.
2. West LM; Northcote PT J. Org. Chem 2000, 65, 445. [PubMed: 10813954]
3. (a)Hood KA; Backstrom BT; West LM; North-cote PT; Berridge MV; Miller JH Anti-Cancer Drug Design 2001, 16, 155; [PubMed: 11962513] (b)Hood KA; West LM; Rouwe B; Northcote PT; Berridge MV; St. Wakefield J; Miller JH Cancer Res 2002, 62, 3356. [PubMed: 12067973]
4. Bollag DM; McQueney PA; Zhu J; Hensens O; Koupal L; Liesch J; Goetz M; Lazarides E; Woods CM Cancer Res 1995, 55, 2325. [PubMed: 7757983]
5. (a)Ghosh AK; Wang Y J. Am. Chem. Soc 2002, 122, 11027;(b)Ghosh AK; Wang Y; Kim JT J. Org. Chem 2001, 66, 8973; [PubMed: 11749630] (c)Pryor DE; O'Brate A; Bilcer G; Diaz JF; Wang Y; Kabaki M; Jung MK; Andreu JM; Ghosh AK; Giannakakou P; Hamel E Biochemistry 2002, 41, 9109. [PubMed: 12119025]
6. Paterson I; Di Francesco ME; Kuhn T Org. Lett 2003, 5, 599. [PubMed: 12583779]
7. Nacro K; Baltas M; Gorrichon L Tetrahedron 1999, 55, 14013.
8. For an excellent review, please see: Kolb HC; Van-Nieuwenhze MS; Sharpless KB Chem. Rev 1994, 94, 2483.
9. Optical purity of the corresponding diol (90% ee) was determined by chiral HPLC analysis (5% 2-propanol/hexane, flow rate 1 mL/min, R_t =5.3 min for the minor isomer and R_t =6.8 min for the major isomer) using Daicel Chiracel OD column.
10. Merger SD; Schreiber SL J. Org. Chem 1994, 59, 7549.
11. (a)Jadhav PK; Bhat KS; Perumaal T; Brown HC J. Org. Chem 1986, 51, 432;(b)Racgerlaa US; Brown HC J. Org. Chem 1991, 56, 401.
12. (a)Ghosh AK; Lei H J. Org. Chem 2002, 67, 8783; [PubMed: 12467389] (b)Mori Y; Kuhara M; Takeuchi A; Suzuki M Tetrahedron Lett 1988, 29, 5419.

13. (a)Ghosh AK; Cappiello J; Shin D *Tetrahedron Lett* 1998, 39, 4651;(b)Ghosh AK; Liu C *Chem. Commun* 1999, 1743;(c)Nicolaou KC; Rodriguez RM; Mitchell HJ; van Delft FL *Angew. Chem., Int. Ed. Engl* 1998, 37, 1874.
14. For an excellent review, see: Grubbs RH; Chang S *Tetrahedron* 1998, 54, 4413.
15. (a)Ghosh AK; Shin D; Mathivanan P *Chem. Commun* 1999, 1025;(b)Ghosh AK; McKee SP; Thompson WJ; Darke PL; Zugay JC *J. Org. Chem* 1993, 58, 1025. [PubMed: 30310240]
16. All new compounds gave satisfactory spectroscopic and analytical results. Lactone **17**: $[\alpha]_{\text{D}}^{20} = +43.28$ (*c* 0.67, CHCl_3); IR (thin film) 1758 cm^{-1} ; $^1\text{H NMR}$ (500 MHz, CDCl_3): δ 7.38–7.30 (m, 5H), 4.60–4.51 (m, 3H), 4.44 (m, 1H), 4.24 (d, $J=7.7$ Hz, 1H), 4.0 (m, 1H), 3.88 (m, 1H), 3.67 (dd, $J=9.9$, 5 Hz, 1H), 3.54 (dd, $J=9.9$, 5.7 Hz, 1H), 2.47 (ddd, $J=14.2$, 8.1, 1.4 Hz, 1H), 2.08 (ddd, $J=14.3$, 7.6, 6.2 Hz, 1H), 1.89 (ddd, $J=14.3$, 6.1, 4.8 Hz, 1H), 1.72 (ddd, $J=14.2$, 12.1, 8.0), 1.50 (s, 3H), 1.40 (s, 3H), 1.38 (s, 6H); $^{13}\text{C NMR}$ (125 MHz): δ 170.6, 138.1, 128.9, 128.3 (2C), 112.1, 109.5, 80.1, 75.3, 74.1, 73.1, 72.9, 72.2, 70.8, 38.6, 34.8, 27.6, 27.3 (2C), 25.7; HRMS (FAB) *m/z* calcd for $\text{C}_{22}\text{H}_{51}\text{O}_7$ ($\text{M}^+\text{+H}$): 407.2070; found: 407.2071.







Figure 1.

**Scheme 1.**

Reagents and conditons: (a) AD mix- α , $\text{CH}_3\text{SO}_2\text{NH}_2$, $^t\text{BuOH-H}_2\text{O}$ (1:1), 0°C , 36 h, (89%); (b) $\text{Me}_2\text{C}(\text{OMe})_2$, PPTS (cat.), Me_2CO , 23°C , 5 h (92%); (c) LiBH_4 , THF, 0°C , 2 h (97%); (d) NaH, BnBr, DMF, 23°C , 4 h (69%); (e) $n\text{Bu}_4\text{N}^+\text{F}^-$, THF, 23°C , 2 h (99%); (f) Dess–Martin, NaHCO_3 , CH_2Cl_2 , 23°C , 2 h; (g) $\text{CH}_2=\text{CHCH}_2\text{B}[(\text{-})\text{-Ipc}]_2$, THF, -78°C , 3 h (71%); (h) $\text{CH}_2=\text{CHCH}_2\text{MgBr}$, Et_2O , 0°C , 1 h (74%); (i) LiAlH_4 , LiI, Et_2O , -78°C , 30 min (87%); (j) $\text{CH}_2=\text{CHCOCl}$, Et_3N , CH_2Cl_2 , 0°C , 1 h (62%); (k) $\text{Cl}_2(\text{PCy}_3)_2\text{Ru}=\text{CHPh}$, CH_2Cl_2 , 40°C , 14 h (90%).

**Scheme 2.**

Reagents and conditions: (a) OsO_4 (cat.), NMO, $\text{Me}_2\text{CO}:\text{H}_2\text{O}$ (7:1), 23°C , 12 h (72%); (b) NaOH, THF- H_2O , 0°C , 14 h; (c) TBDMSCl, imidazole, DMF, 23°C , 18 h; (d) CH_2N_2 , Et_2O , 0°C , 0.5 h (80% for three steps); (e) AD mix- β , $\text{CH}_3\text{SO}_2\text{NH}_2$, $t\text{BuOH}:\text{H}_2\text{O}$ (1:1), 0°C , 72 h (72%); (f) $n\text{Bu}_4\text{N}^+\text{F}^-$, THF, 23°C , 3 h; (g) $\text{Me}_2\text{C}(\text{OMe})_2$, PPTS (cat.), Me_2CO , 23°C , 24 h (63% for two steps).